Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
The conference call will take place at 9:00 a.m. EDT, on Thursday, May 15,2008. Interested participants should call 800-762-9058 within the UnitedStates, or US + 1-480-629-9039 if calling internationally. The conference IDis 3879213. It is advisable to dial in approximately 5-10 minutes prior to9:00 a.m. EDT.
If you are unable to participate in the call at the scheduled time, aplayback will be available on Thursday, May 15, 2008 at 12:00 p.m. EDT throughThursday, May 29, 2008 at 11:59 p.m. EDT. To listen to the playback, pleasecall 800-406-7325 from within the United States, or US +1-303-590-3030internationally. Please use pass code 3879213 for the replay.
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional ChineseMedicine ("TCM") in China. It was established in 1994 and acquired by thecurrent management team in August 2003. It has a comprehensive productportfolio of 34 modernized TCMs in the market, 22 of which are listed in thehighly selective National Medicine Catalog of the National Medical InsuranceProgram. Tianyin owns and operates two GMP manufacturing facilities and anR&D platform supported by leading Chinese academic institutions. The Companyhas a pipeline of 51 pharmaceutical products pending approval. Tianyin has anextensive nationwide distribution network throughout China with a sales forceof 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province withtwo manufacturing facilities and a total of 1,187 employees. Tianyin achievedrevenue of $20.4 million and net income of $3.95 million in FY2007 ending June30, 2007.
Safe Harbor Statement
The Statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.For more information, please contact: For the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO Tel: +86-158-2122-5642 Email: Allen.email@example.com Investors: HC International, Inc. Alan Sheinwald Tel: +1-914-669-0222 Email: Alan.Sheinwald@hcinternational.net
SOURCE Tianyin Pharmaceutical, Co., Inc.
You May Also Like